---
title: "Travere Therapeutics Executives Sell Shares Following PSU Vesting and Under Pre-Arranged Trading Plans"
date: "2025-02-13 10:30:00"
summary: "Reporter NameRelationshipTypeAmountSEC FilingInrig JulaCHIEF MEDICAL OFFICERSell$60,425Form 4Dube Eric MCHIEF EXECUTIVE OFFICERSell$273,455Form 4Heerma PeterCHIEF COMMERCIAL OFFICERSell$137,275Form 4Calvin SandraSVP, CHIEF ACCOUNTING OFFICERSell$1,356,100Form 4Reed Elizabeth ESVP, GC &amp; CORPORATE SECRETARYSell$188,240Form 4Travere Therapeutics has seen a series of stock transactions by its top executives, as reported in recent SEC Form 4 filings. Jula Inrig,..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

| Reporter Name | Relationship | Type | Amount | SEC Filing |
| --- | --- | --- | --- | --- |
| Inrig Jula | CHIEF MEDICAL OFFICER | Sell | $60,425 | [Form 4](https://www.sec.gov/Archives/edgar/data/1902368/000141588925003819/xslF345X05/form4-02132025_020211.xml) |
| Dube Eric M | CHIEF EXECUTIVE OFFICER | Sell | $273,455 | [Form 4](https://www.sec.gov/Archives/edgar/data/1763494/000141588925003820/xslF345X05/form4-02132025_020239.xml) |
| Heerma Peter | CHIEF COMMERCIAL OFFICER | Sell | $137,275 | [Form 4](https://www.sec.gov/Archives/edgar/data/1789617/000141588925003821/xslF345X05/form4-02132025_020229.xml) |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER | Sell | $1,356,100 | [Form 4](https://www.sec.gov/Archives/edgar/data/1882909/000141588925003822/xslF345X05/form4-02132025_020258.xml) |
| Reed Elizabeth E | SVP, GC & CORPORATE SECRETARY | Sell | $188,240 | [Form 4](https://www.sec.gov/Archives/edgar/data/1438533/000141588925003823/xslF345X05/form4-02132025_020224.xml) |

Travere Therapeutics has seen a series of stock transactions by its top executives, as reported in recent SEC Form 4 filings. Jula Inrig, the company's Chief Medical Officer, sold 2,568 shares at a price of $23.5302 per share, totaling $60,425, to cover tax obligations from vested performance restricted stock units (PSUs). Following this sale, Inrig directly owns 89,602 shares.

Eric M. Dube, CEO and Director, sold 11,375 shares at $24.04 per share, amounting to $273,455, under a pre-arranged 10b5-1 trading plan established on March 15, 2024. Post-transaction, Dube's direct ownership stands at 419,173 shares.

Peter Heerma, Chief Commercial Officer, executed sales of 5,642 shares across February 11 and 12, 2025, at prices ranging from $23.5302 to $25.00 per share, for a total of $137,275. Heerma now directly owns 125,066 shares.

Calvin Sandra, SVP and Chief Accounting Officer, sold 54,244 shares at $25.0 per share, totaling $1,356,100, and currently directly owns 54,410 shares.

Elizabeth E. Reed, SVP, GC & Corporate Secretary, sold 8,000 shares at $23.53 per share, totaling $188,240, under a Rule 10b5-1(c) plan adopted on March 15, 2024, to cover tax obligations from vested PSUs. Reed's direct ownership after the sale is 89,482 shares.

[TradingView](https://www.tradingview.com/news/tradingview:90dc8fcbb4133:0-travere-therapeutics-executives-sell-shares-following-psu-vesting-and-under-pre-arranged-trading-plans/)
